Bionime Corporation

Equities

4737

TW0004737002

Medical Equipment, Supplies & Distribution

End-of-day quote Taiwan S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
69.9 ^TWD	-1.13%		+2.79%	-6.55%

03-15	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-14	Bionime Corporation Announces Dividend for the Year Ended December 31, 2023	CI

Bionime Corporation Announce Demise of Lin,Ming-Hsiang, Institutional Director

January 10, 2022 at 10:23 am

Bionime Corporation announced death in representative of the Company's institutional director. Name of the previous position holder: Lin,Ming-Hsiang; Resume of the previous position holder: Deputy General Manager in charge of Finance, Hua Eng Wire & Cable Co.,Ltd.

Latest news about Bionime Corporation

Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Bionime Corporation Announces Dividend for the Year Ended December 31, 2023	03-14	CI
Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Bionime Corporation Announces TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License	13/10/23	CI
Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer	18/08/23	CI
Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Bionime Corporation Announces Appointment of Aling Lai as New Member to the Remuneration Committee	09/08/23	CI
Bionime Corporation Appoints Aling Lai as Additional Member of Audit Committee	30/06/23	CI
Bionime Corporation Approves Cash Dividends, Payable on August 18, 2023	30/06/23	CI
Bionime Corporation Announces Election of Aling Lai as an Additional Independent Director	30/06/23	CI
Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Bionime Corporation Revises Cash Dividend for 2022	10/05/23	CI
Bionime Corporation Appoints Chen Hui-Zhen as Corporate Governance Officer	10/05/23	CI
Bionime Corporation Announces Cash Dividend for 2022	14/03/23	CI
Bionime Corporation Announces Resignation of Tai,Tsung-Kai as Institutional Director, Effective April 30, 2023	03/03/23	CI
Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Bionime Corporation Approves the Factory Area to Expand Building the Clean Room to Accommodate Production Equipment and Increase Production Capacity	09/11/22	CI
Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System	02/09/22	CI
Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Bionime Corporation Announces Members of the First Order Audit Committee of the Company	05/07/22	CI
Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	29/03/22	CI
Bionime Corporation Announces Cash Dividend for 2021	22/03/22	CI
Bionime Corporation Announces Replacement of the Representative of the Its Institutional Director	28/01/22	CI
Bionime Corporation Announce Demise of Lin,Ming-Hsiang, Institutional Director	10/01/22	CI

Chart Bionime Corporation

Duration

Period

More charts

Company Profile

Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

27/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

69.9 TWD

Average target price

80 TWD

Spread / Average Target

+14.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIONIME CORPORATION	-6.55%	131M
BIOMÉRIEUX	-1.29%	12.64B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.47%	8.46B
DIASORIN S.P.A.	+5.68%	5.66B
LANTHEUS HOLDINGS, INC.	+22.61%	5.27B
AUTOBIO DIAGNOSTICS CO., LTD.	-2.03%	4.49B
10X GENOMICS, INC.	-53.56%	3.11B
ANDON HEALTH CO., LTD.	+19.30%	2.87B
VITROLIFE AB	-8.42%	2.23B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.89B

Diagnostic & Testing Substances